Abstract
Tumors can arise from any of the cell types that make up the pituitary gland. The role of medical therapy in pituitary adenomas varies depending on the tumor subtype. In the case of prolactinomas, medical therapy is the primary treatment. For all other tumors of pituitary origin, surgery is the primary therapy with medical therapy playing an adjunctive role sometimes in conjunction with radiation therapy. This brief chapter gives an overview of the use of medical therapy in treating pituitary tumors. Ultimately, a multidisciplinary approach is beneficial in the management of most pituitary tumors.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kars M, Souberein PC, Herings RM, Romijn JA, Vandenbroucke JP, DeBoer A, Dekkers OM. Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. J Clin Endocrinol Metab. 2009;94(8):2729–34.
Schlechte J, Walkner L, Kathol M. A longitudinal analysis of premenopausal bone loss in healthy women and women with hyperprolactinemia. J Clin Endocrinol Metab. 1992;75(3):698–703.
Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechter JA, Wass JA. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273–88.
Nieman L, Biller BMK, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM. The diagnosis of Cushing’s syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(5):1526–40.
Kelly DF. Transsphenoidal surgery for Cushing’s disease: a review of success rates, remission predictors, management of failed surgery, and Nelson’s syndrome. J Neurosurg Focus. 2007;23(3): 1–6.
Petrossians P, Thonnard A, Beckers A. Medical treatment in Cushing’s syndrome: dopamine agonists and cabergoline. Neuroendocrinology. 2010;92 Suppl 1:116–9.
Pedroncelli A. Medical treatment of Cushing’s disease: somatostatin analogues and pasireotide. Neuroendocrinology. 2010;92 Suppl 1:120–4.
Castinetti F, Brue T, Conte-Devolx B. The use of glucocorticoid receptor antagonist mifepristone in Cushing’s syndrome. Curr Opin Endocrinol Diabetes Obes. 2012;19(4):295–9.
Katznelson L, Atkinson JLD, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly—2011 update. Endocr Pract. 2011;17 Suppl 4:1–44.
Ludlam WH, Anthony L. Safety review: dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors. Adv Ther. 2011;28(10):825–41.
Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2011;96(5): 1327–35.
Buhk JH, Jung S, Psychogios MN, Goricke S, Hartz S, Schulz-Heise S, Klingebiel R, Forsting M, Bruckmann H, Dorfler A, Jordan M, Buchfelder M, Knauth M. Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study. J Clin Endocrinol Metab. 2010;95(2):552–8.
Sherlock M, Woods C, Sheppard MC. Medical therapy in acromegaly. Nat Rev Endocrinol. 2011;7:291–300.
Meyers A, Hatanpaa KJ, Madden C, Lingvay I. Thyrotropin-secreting adenoma in a patient with primary hypothyroidism. Endocr Pract. 2011;17(6):135–9.
Socin HV, Chanson P, Delemer B, Tabarin A, Rohmer V, Mockel J, Stevenaert A, Beckers A. The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. Eur J Endocrinol. 2003;148(4):433–42.
Macchia E, Gasperi M, Lombardi M, Morselli L, Pinchera A, Acerbi G, Rossi G. Clinical aspects and therapeutic outcome in thyrotropin-secreting pituitary adenomas: a single center experience. J Endocrinol Invest. 2009;32:773–9.
Beck-Peccoz P, Persani L, Mannavola D, Campi I. TSH-secreting adenomas. Best Pract Res Clin Endocrinol Metab. 2009;23:597–606.
Daousi C, Foy PM, MacFarlane IA. Ablative thyroid treatment for thyrotoxicosis due to thyrotropin-producing pituitary tumors. J Neurol Neurosurg Psychiatry. 2007;78(1):93–5.
Knoepfelmacher M, Danilovic DLS, Nasser RHRR, Mendonca BB. Effectiveness of treating ovarian hyperstimulation syndrome with cabergoline in two patients with gonadotropin-producing pituitary adenomas. Fertil Steril. 2006;86(3):15–8.
Chen Y, Wang CD, Su ZP, Chen YX, Cai L, Zhuge QC, Wu ZB. Natural history of postoperative nonfunctioning pituitary adenomas: a systematic review and meta-analysis. Neuroendocrinology. 2012;96(4):333–42.
Chang EF, Zada G, Kim S, Lamborn KR, Quinones-Hinojosa A, Tyrrell JB, Wilson CB, Kunwar S. Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas. J Neurosurg. 2008;108:736–45.
Shomali ME, Katznelson L. Medical therapy of gonadotropin-producing and nonfunctioning pituitary adenomas. Pituitary. 2002; 5(2):89–98.
Dekkers OM, Pereira AM, Romijn JA. Treatment and follow-up of clinically nonfunctioning pituitary macroadenomas. J Clin Endocrinol Metab. 2008;93(10):3717–26.
Pereirra AM, Biermasz NR. Treatment of nonfunctioning pituitary adenomas: what were the contributions of the last 10 years? Ann Endocrinol (Paris). 2012;73(2):111–6.
Cooper O, Melmed S. Subclinical hyperfunctioning pituitary adenomas: the silent tumors. Best Pract Res Clin Endocrinol Metab. 2012;26:447–60.
Cooper O, Ben-Shlomo A, Bonert V, Bannykh S, Mirocha J, Melmed S. Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes. Horm Cancer. 2010; 1(2):80–92.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this chapter
Cite this chapter
Hopkins, R.L. (2015). Pituitary Tumors: Viewpoint— Medical Therapy. In: Chin, L., Regine, W. (eds) Principles and Practice of Stereotactic Radiosurgery. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-8363-2_29
Download citation
DOI: https://doi.org/10.1007/978-1-4614-8363-2_29
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-8362-5
Online ISBN: 978-1-4614-8363-2
eBook Packages: MedicineMedicine (R0)